Skip to main content

Month: April 2025

Hiab’s interim report January–March 2025: Profitability improved driven by strong execution in all divisions

HIAB CORPORATION, INTERIM REPORT JANUARY–MARCH 2025, 30 APRIL 2025 AT 8:00 AM (EEST) Hiab’s interim report January–March 2025: Profitability improved driven by strong execution in all divisions Key takeaways from the quarterHiab became a standalone listed company on 1 April Orders received amounted to EUR 378 million and remained on the comparison period’s level. Decrease in Americas offset by increase in EMEA and Asia-Pacific Comparable operating profit improved to EUR 66 million due to strong execution on commercial and supply chain actions Robust cash generation continued and balance sheet is very strong Elevated market uncertainty due to the increased trade tensions Outlook for 2025 unchanged: Hiab estimates its continuing operations’ comparable operating profit margin in 2025 to be above 12.0 percent (2024: 13.2 percent)Unless...

Continue reading

Ontex shows margin resilience in Q1, and confirms full year outlook

Regulated informationRevenue of €451 million, 2.8% lower LFL, with soft market demand partly offset by mix improvement in Europe and double-digit volume growth in North America; Adj. EBITDA margin resilient at 11.2%, with strong delivery of the cost transformation program ; Divestment of Brazilian business successfully concluded; Long-term financing secured, with new €400 million bond maturing in 2030; Full year outlook confirmed, with volume gains in H2 as main driver.  CEO quote Gustavo Calvo Paz, Ontex’s CEO, said: “These results demonstrate Ontex’s improved resilience in a more challenging economic environment, providing us confidence to confirm our full-year outlook. While we may encounter occasional challenging quarters, these are temporary fluctuations not indicative of the long-term trends our business is built on. Our focus...

Continue reading

dsm-firmenich Q1 2025 trading update

Press ReleaseKaiseraugst (Switzerland), Maastricht (Netherlands), April 30, 2025 dsm-firmenich Q1 2025 trading update Management Report Q1 2025 highlightsGood start to the year with strong organic sales and earnings growth Progressing well on 2025 strategic plan Sale of Feed Enzymes business for €1.5 billion announced Animal Nutrition & Health exit process advancing as planned €1 billion share buyback program commenced in April FY 2025 outlook unchanged: Adjusted EBITDA at least €2.4 billionKey figuresin € millions Q1 2025 Q1 2024 % ChangeSales 3,274 3,071 7Organic sales growth (%) 8    Adj. EBITDA 650 463 40Adj. EBITDA margin (%) 19.9 15.1         Dimitri de Vreeze, CEO, commented: “We are pleased to report a strong performance in the first quarter, with significant growth across our businesses and the...

Continue reading

Nexans – Q1 2025, promising start to the year

   First-quarter 2025 financial information Promising start to 2025Electrification segment, a key driver of our growth, delivering +6.8% organic growth in Q1 2025No material impact from “US Liberation Day” Tariff2025 guidance confirmedFirst-quarter 2025 standard sales of €1,815.4 million, up +4.1% organically year-on-year:Electrification businesses were up +6.8% organically, with double digit organic growth in PWR-Transmission segment. PWR-Grid and PWR-Connect remained well-oriented Record adjusted backlog for PWR-Transmission, mainly subsea-driven, at €8.1 billion, up +9.7% compared to €7.4 billion at end of December 2024Major framework agreement, valued at more than €1 billion, was secured with RTE in March 2025 for the design, manufacturing, and supply of HVDC cables, which will be used to connect offshore wind...

Continue reading

Equinor to commence second tranche of the 2025 share buy-back programme

Equinor (OSE: EQNR, NYSE: EQNR) will after the annual general meeting 14 May 2025 commence the second tranche of up to USD 1,265 million of the share buy-back programme for 2025, as announced in relation with the first quarter results 30 April 2025. Execution of share buy-back under the tranche is subject to renewal of a board authorisation for share buy-back from the annual general meeting 14 May 2025 and agreement with the Norwegian State regarding share buy-back. In this second tranche of the share buy-back programme for 2025, shares for up to USD 417.5 million will be purchased in the market, implying a total second tranche of up to USD 1,265 million including shares to be redeemed from the Norwegian State. The tranche will end no later than 21 July 2025. Equinor announced at the Capital Market Update in February 2025 a share buy-back...

Continue reading

Equinor ASA: Key information relating to cash dividend for first quarter 2025

Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for first quarter 2025. Cash dividend amount: 0.37 Announced currency: USD Last day including rights: 15 August 2025 Ex-date Oslo Børs : 18 August 2025 Ex-date New York Stock Exchange: 19 August 2025 Record date: 19 August 2025 Payment date: 29 August 2025 Date of approval: 29 April 2025 Other information: The cash dividend per share in NOK will be communicated 25 August 2025. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

Continue reading

Equinor first quarter 2025 results

Equinor (OSE:EQNR, NYSE:EQNR) delivered adjusted operating income* of USD 8.65 billion and USD 2.25 billion after tax in the first quarter of 2025. Equinor reported net operating income of USD 8.87 billion and net income at USD 2.63 billion. Adjusted net income* was USD 1.79 billion, leading to adjusted earnings per share* of USD 0.66. Strong financial and operational performanceStrong financial results and cash flow Solid oil and gas productionStrategic progressSuccessful start-up of the Johan Castberg and Halten East fields Final investment decision on Northern Lights phase 2Capital distributionFirst quarter cash dividend of USD 0.37 per share Proposed second tranche of share buy-back of up to USD 1.265 billion Expected total capital distribution for 2025 of up to USD 9 billionAnders Opedal, President and CEO of Equinor ASA: “Equinor...

Continue reading

Societe Generale: First quarter 2025 earnings

RESULTS AT 31 MARCH 2025 Press release                                                        Paris, 30 April 2025 STRONG QUARTERLY RESULTS, AHEAD OF OUR 2025 TARGETS Quarterly revenues of EUR 7.1 billion, +6.6% vs. Q1 24 and +10.2% excluding asset disposals (vs. an annual target of more than +3%). Positive contribution from all businesses, driven by a strong rebound in French Retail Banking, a solid performance of Global Banking and Investor Solutions and a sustained activity in Mobility, International Retail Banking and Financial Services Strict cost management with operating expenses down -4.4% vs. Q1 24, excluding asset disposals. Ahead of our 2025 target to reduce operating expenses by more than -1%, excluding asset disposals Cost-to-income ratio at 65.0% in Q1 25, ahead of our 2025 target (100%NSFR 115% 117% >100%In EURbn 31/03/2025 31/12/2024Total...

Continue reading

Hepsor AS consolidated unaudited interim report for Q1 2025

Hepsor’s consolidated sales revenue for Q1 2025 was 8.2 million euros (Q1 2024: 2.3 million euros). The Group’s net loss for the first quarter was 0.1 million euros (Q1 2024: 1.0 million euros), of which the net loss attributable to the owners of the parent was 0.2 million euros (Q1 2024: 0.9 million euros). In coordination with the Group’s Supervisory Board, the Management Board proposes to distribute 1,0 million euros (EUR 0.26 per share) in dividends to shareholders in 2025 from the profits of previous periods. Based on the share price as of 31 March 2025, this results in a dividend yield of 6.9%. Development projects under construction and available for sale In the first quarter of 2025, we continued the construction and sales of projects in our development portfolio. Customer interest in Hepsor’s developments has remained...

Continue reading

Basel Medical Group Completes Acquisition of Bethesda Medical to Strengthen Healthcare Ecosystem in Singapore and Southeast Asia 

Singapore , April 30, 2025 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL), today announced the closing of the acquisition of Bethesda Medical Pte. Ltd., a leading Singapore-based healthcare provider specializing in diagnostic imaging and outpatient care. The acquisition marks a significant step in Basel Medical Group’s strategic expansion in Singapore and the broader Southeast Asian healthcare market. About Bethesda Medical Pte. Ltd. Bethesda Medical started its first medical establishment in 1995. This year marks their 30 years’ anniversary, and at same time, marks the commencement of a new journey with Basel Medical Group. Bethesda Medical has previously won government tenders in Singapore and has been active with both public and private sectors of work. The group not only covers occupational health services for foreign...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.